Bluebird Bio's gene therapy for neurological disorder gets FDA panel backing




  • In Health
  • 2022-06-09 21:59:16Z
  • By Reuters
 

By Mrinalika Roy

(Reuters) -Advisers to the U.S. Food and Drug Administration on Thursday voted to recommend approval of bluebird bio's treatment for a rare neurological disorder, bringing it closer to becoming the third gene therapy to be available in the United States.

All 15 committee members voted unanimously that the benefits of eli-cel for treatment of cerebral adrenoleukodystrophy (CALD) in patients below 18 years who do not have a matched sibling for stem cell transplant, outweigh its risks.

"Today, we are one step closer to delivering a potentially lifesaving therapy for CALD ... We remain committed to working with the FDA as it completes its review of eli-cel," Chief Executive Officer Andrew Obenshain said.

The decision on eli-cel is a big boost for the company after it had in March flagged "going concern" doubts following regulatory setbacks.

A negative outcome was widely expected after FDA staff flagged safety and efficacy concerns in briefing documents published on Tuesday, including whether the treatment's benefits outweigh risk of Myelodysplastic syndrome (MDS), a type of cancer that appeared in three trial patients.

"Even with the problems that exist for this treatment, it certainly shows significant benefit that boys (who suffer from CALD) right now can't wait on a better more perfect treatment," said committee member Dr. Stephanie Keller.

CALD is a rare genetic condition that causes the buildup of very long chain fatty acids in the brain and spinal cord. It typically occurs in young boys between the ages of 3 and 12.

If the FDA follows the recommendation and approves eli-cel, it will be the third gene therapy available for use in the United States, following Spark Therapeutics' Luxturna and Novartis' Zolgensma.

The panel will again convene on Friday to discuss bluebird's other gene therapy beti-cel for the treatment of Beta-thalassemia patients dependent on blood transfusions.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila and Maju Samuel)

COMMENTS

More Related News

Emergent receives FDA warning letter over quality control issues
Emergent receives FDA warning letter over quality control issues

The FDA pointed to deficiencies in cleaning and maintenance of equipment to prevent contamination of drug product and also recommended the company review its...

Want to be sure you don
Want to be sure you don't have COVID? FDA now says you'll need to pass 3 home tests

The FDA now recommends taking 3 home tests over 5 days to be more confident you don't have COVID, especially if you fear you've been exposed.

FDA: Take 3 home tests if exposed to COVID to boost accuracy
FDA: Take 3 home tests if exposed to COVID to boost accuracy
  • US
  • 2022-08-11 20:00:58Z

Previously, the Food and Drug Administration had advised taking two rapid antigen tests over two or three days to rule out infection. Thursday's update...

FDA chief backs alternate method for injecting Bavarian Nordic
FDA chief backs alternate method for injecting Bavarian Nordic's monkeypox shot
  • US
  • 2022-08-11 16:43:29Z

The company had on Tuesday said there was some evidence that a shot of Jynneos between the layers of the skin could result in increased reactions compared to...

Bottling the monkeypox vaccine could take until early 2023
Bottling the monkeypox vaccine could take until early 2023

The Biden administration is amid negotiations with several companies to bottle millions of new monkeypox shots. But officials say it could take months for...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Health